INTRODUCTION
Pseudoxanthoma elasticum (PXE) was first described as an independent disease entity in 1896 by the French dermatologist Jean Darier, who characterized it histologically as a progressive fragmentation of the elastic tissue of the papillary dermis (1).
Subsequently, PXE was recognized as a multisystem disorder of the elastic tissue leading not only to skin disease but also to ocular (angioid streaks) (2) and vascular complications (3) . The typical cutaneous manifestations of PXE ('cobblestone'-like changes with a predilection for flexural surfaces) (1, 3, 4) are mostly cosmetic in nature; however, its cardiovascular complications, while rare, can be life threatening (mainly gastrointestinal hemorrhage and coronary disease) (5) (6) (7) (8) and its ocular manifestations (fractures of Bruchs' membrane resulting in so-called 'angioid streaks' followed by neovascularization) are common, leading to retinal hemorrhage and consecutive central blindness in about half of all affected individuals (2, 3) .
PXE represents a paradigm for disorders of heterotopic tissue calcification, with the ultrastructural defect characterized by a centrifugally progressive accumulation of calcium salt deposits (CaCO 3 and CaPO 4 ) within elastic fibers, starting in the core and leading, eventually, to their fracture and destruction (9) (10) (11) . Previous efforts to link the disease in limited numbers of families to several potential candidate genes (such as elastin, fibrillins I and II and lysyl oxidase) were negative or equivocal (12) ; likewise, no biochemical abnormality, except for an accumulation of glycosaminoglycans in the affected skin (13) , has reproducibly been shown to be associated with the disease. In the majority of cases PXE appears to be inherited as an autosomal recessive trait (horizontal pattern of inheritance) with high penetrance and early onset (on average at 13 years of age), occurring about twice as often in females as in males. In ∼10% of pedigrees an autosomal dominant mode of transmission (vertical transmission pattern) appears to be operative. The phenotypic manifestations of PXE show considerable variance, which was found to be unrelated to mode of apparent inheritance (14) , with regard to system(s) affected and severity of disease (3, 15) . Presently, the most widely accepted gold standard for diagnosis of PXE relies on positive von Kossa staining in biopsy material from affected skin, indicating calcification and fracture of elastic fibers.
In this study we report mapping of the recessive and dominant forms of PXE to the same chromosomal region, 16p13.1, an area without any apparent candidate gene for the disease. Column two indicates the number of families included in the initial genome screen analysis using SAGE, carried out in all families showing apparent recessive inheritance that were available at the initiation of molecular genetic studies (at this time the family with five affected siblings was considered autosomal recessive; this was later revised to autosomal dominant upon availability of additional information) and using only affected sib pairs (no other family members). Columns 3 and 4 present information on pedigrees selected for parametric linkage analysis according to apparent mode of inheritance and under inclusion of all available family members regardless of affection status. Numbers of affected sib pairs in a family with n affected sibs are calculated as n(n -1)/2. n/a, not applicable. 
RESULTS
Most of the patients and families investigated in the present study had originally been recruited for a previous clinical study of PXE performed at the University of Colorado Health Science Center and at Texas Tech University Health Sciences Center over a 20 year period from 1973 to 1993 (3). Others were obtained from the database of the National Association for PXE. Only biopsy-proven diagnoses with positive von Kossa staining were considered as PXE cases. Except for eight families, all showed a strictly horizontal pattern of disease prevalence, suggestive of autosomal recessive inheritance. In keeping with previous studies, we observed a female-to-male ratio of ∼2:1 among our patients.
We followed a two stage strategy to map the causative gene, designated PXE (the gene name PXE has been approved by the HUGO Nomenclature Committee). First, a genome-wide screen using a panel of tri-and tetranucleotide single sequence length polymorphisms (16) (17) (18) was performed on 73 affected sib pairs belonging to 38 families (see Table 1 ). Data were analyzed by non-parametric allele sharing methods (SIBPAL) (19) (20) (21) . Three markers on the short arm of chromosome 16, D16S2619, D16S748 and D16S403, were found to show significant excess allele sharing compared with chance (61 versus 50%, P = 0.0005, 66 versus 50%, P = 0.0002, and 67 versus 50%, P = 0.0003, respectively).
Based on this information, we proceeded to genotype all 264 affected and unaffected subjects belonging to the 42 pedigrees with an apparently recessive inheritance pattern, as well as those belonging to the eight families with an apparently dominant inheritance pattern, using a set of high resolution, highly informative markers (PIC > 0.7). Twelve microsatellite markers fulfilling these conditions were tested. They were selected from the collections assembled by the Cooperative Human Linkage Center (CHLC; Extended Généthon V2 Recombination-Minimization Sex Averaged Map, v.4.0) (16) (17) (18) and by Généthon (22) . All were localized in the area of interest and had an average spacing of 2.9 cM and an average polymorphism information content of 0.77.
Forty five of the 50 families had affected relative pairs other than parent-child pairs; they underwent non-parametric analysis by both the APM (23) and SIBPAL (21) methods. Results from these analyses were consistent with the original findings of linkage to the region, i.e. to chromosome 16p13, and with each other (Table 2 ). Both analyses provide significant evidence of linkage for markers spanning the region D16S406-D16S403, with a peak around D16S500.
Intermarker distances and orders were estimated using the family data and ILINK (24) and are shown in Table 3 . Parametric two point maximum lod scores (MLS) were then calculated for all 50 pedigrees assuming either autosomal recessive or autosomal dominant models of transmission respectively (Table 3 ). An MLS of 21.27 was found for D16S500 at θ = 0.045 assuming the recessive model and an MLS of 14.53 for the same marker at θ = 0.011 under an assumption of dominant inheritance. Model-based multipoint linkage analysis results using GENEHUNTER (25) are shown in Figure 1 . Under the recessive model (Fig. 1, graph AR) an MLS of 21.8 was observed between D16S3079 and D16S3103. Allowing for heterogeneity, this lod score increased to 23.7 with an estimated 88% of families linked. The MLS obtained under the dominant model (Fig. 1, graph AD) was 16.9. Non-parametric multipoint linkage analysis using GENEHUNTER NPL revealed similarly significant results (Fig.  1, graph NPL) , with a maximum NPL score of 9.81 (P = 2.47 × 10 -25 ) close to D16S405. The information content of the map of chromosome 16 markers was ≥80% across the entire region. Thus both the model-based and model-free analyses provide highly significant evidence of linkage between PXE and markers in this region on chromosome 16.
To address the issue of heterogeneity across the sample in an unbiased fashion, we conducted a number of analyses using the program HOMOG (26) on multipoint lod scores obtained with VITESSE (27) . These analyses were designed to evaluate the relative likelihood of: (i) the presence of linkage heterogeneity with a fraction of the families displaying genetic linkage of the disease to chromosome 16 and the remaining families not showing linkage; (ii) the possibility of distinct loci coding for the disease in different families; (iii) the presence of different modes of inheritance at the same locus.
First, we tested, across all families, the evidence for locus heterogeneity assuming either autosomal recessive or autosomal dominant modes of inheritance (allowing a fraction of families not to be linked to the chromosome 16p13 locus). As illustrated in Table 4A , locus heterogeneity was favored over linkage with homogeneity in both the recessive and the dominant models, with likelihood ratios of 148.2 and 8.8, based on 90 and 95% of families linked to chromosome 16, respectively and with an associated shift of the maximum likelihood placement for PXE from between D16S3079 and D16S3103 to between D16S500 and D16S405 under both models. Next, we tested for locus heterogeneity within the 25 cM region of interest on chromosome 16p13, assuming two closely linked causative loci to account for the disease in all families (Table 4B) . As before, evidence of locus heterogeneity was favored for both the recessive and dominant models, with likelihood ratios of 4.30 θ 10 4 and 299.6 respectively over the single locus model. Imposing an autosomal recessive mode of inheritance, 85% of families showed linkage to the D16S3079-D16S3103 region, whereas the remainder showed linkage to D16S406. When a dominant mode of transmission was imposed, 70% of families showed linkage to D16S405 and the remaining 30% to D16S3103. Last, we compared both the general locus heterogeneity models (H 2 s from Table 4A ) with a model of allelic heterogeneity in which different modes of transmission were possible in individual families, consistent with clinical observations. This analysis favored, with a likelihood ratio of 4 × 10 3 , the latter scenario over the former two, with 75% of families appearing to be linked under the recessive model to a region midway between D16S500 and D16S405 and the remaining 25% best fitting a dominant model with linkage to D16S500. Twelve highly informative markers (PIC > 0.7) were typed in all available members of all families. Intermarker distances were calculated using all available pedigree members. Intermarker distances and lod scores for the linear order of markers indicated were determined using ILINK (24) and are represented in columns 2 and 3 on the lines between markers, indicating that they pertain to the interval between two markers. Orientation of the map is represented as telomeric to centromeric, from top to bottom. Abbreviations: MLE, maximum likelihood estimates; cM, centiMorgan (Kosambi); lod, lod score; n, number of alleles encountered; PIC, polymorphism information content; θ, recombination fraction; rec, all families analyzed under assumptions of recessive inheritance; dom, all families analyzed under assumptions of dominant inheritance. Chromosome 16 multipoint lod scores from all 50 families were examined using HOMOG to test for linkage heterogeneity in general (A), for locus heterogeneity assuming two linked loci on chromosome 16p13 (B) and for allelic versus locus heterogeneity (C). AD, autosomal dominant; AR, autosomal recessive; Max lnL, maximum log likelihood; LR, likelihood ratio; α 1 and α 2 , proportion of families linked and unlinked (A), linked to either locus on chromosome 16p13 (B) or autosomal recessive and autosomal dominant (C) respectively. In (C) the H 2 s are identical to those from (A) and the LR represents H 3 versus H 2A /H 2B . This test also allows for a certain proportion (α 3 ) of families to be unlinked; in our data α 3 was estimated to be 0. Region 1 and Region 2 , maximum likelihood placement of the two modeled loci on chromosome 16p13 (B) and of loci linked to phenotype in an autosomal recessive and autosomal dominant mode respectively. Human Molecular Genetics, 1997, Vol. 6, No. 11 1827
DISCUSSION
Our present data provide robust evidence that PXE maps to chromosome 16p13.1, within a 4.8 cM region between D16S500 and D16S3103. A review of integrated map data available for chromosome 16 (28) reveals that the region of interest (16p13.1) has been saturated with ordered mega-YAC contigs as well as with cosmid and flow-sorted mini-YAC contigs. So far only two genes, MRP and MHY11, which code for a multiple drug resistance-associated protein and for smooth muscle myosin heavy chain-11 respectively, have been mapped to this region, which also represents the breakpoint for a pericentric inversion, in(16)(p13q22), associated with acute myeloid leukemia. The homologous region in the mouse, which maps to mouse chromosome 16, likewise does not contain any apparent candidate genes for PXE. Publicly accessible EST databases have also so far failed to point to a candidate disease gene. Whereas our analyses provide strong evidence either for locus heterogeneity with two closely linked, but distinct, disease loci or for allelic heterogeneity, they do not presently allow a distinction between the two (although the results tend to favor the latter) and they may even be compatible with both. If, indeed, we are witnessing allelic heterogeneity with both recessive and dominant forms of PXE resulting from molecular variations of the same gene, then this raises intriguing questions about the nature of the gene product and of its respective mutations. By analogy to the hypothesis advanced for rhodopsin-linked retinitis pigmentosa, one of the few similar examples of allelic heterogeneity giving rise to dominant and recessive variants of the same disease (29, 30) , one might suspect the presence of unstable or non-translated 'null' mutants in the recessive and of structurally abnormal (dominant negative acting) gene products in the dominant form of the disease.
Our localization of the causative gene is sufficiently precise to allow genetic diagnosis of affection or carrier status by linkage analysis in families with at least one affected member for both dominant and recessive forms of PXE. We expect that a continued search for additional informative meioses, coupled with ongoing efforts at targeted marker development and positional cloning, will lead us to the discovery of the causative gene and, in due course, open up specific approaches to prevention or therapy of PXE and its complications. Perhaps even more importantly, the status of PXE as a model for disorders of aberrant tissue calcification may give the present results potentially broader implications for our understanding of a number of similar disease states characterized by abnormal tissue calcification.
MATERIALS AND METHODS

Collection of PXE families and establishment of a PXE DNA repository
Recruitment of patients and their family members was done by K.H.N. at the Clinical Coordinating Center in Lubbock, based on this investigator's clinical database. Clinical data and blood samples were collected over a 2 year period from families with two or more affected individuals. Affection status was confirmed based on positive von Kossa staining in biopsy material in all patients. Only individuals older than 30 years who showed no evidence of cutaneous and/or retinal lesions were considered as unaffected family members for linkage analyses. All participants in the study provided written, informed consent using a form that was approved by the Institutional Review Board at Texas Tech University Health Sciences Center.
High molecular weight genomic DNA was extracted from 1 ml EDTA-anticoagulated whole blood using a commercially available, adsorption-based method (QIAmp; Qiagen), and stored in multiple aliquots in 0.1× TE at -80_C.
Genetic markers and genotyping
A subset of 169 CHLC microsatellite tri-and tetranucleotide markers (Weber 6a) with an average heterozygosity of 78% and an average spacing of 24.2 cM was purchased from Research Genetics (Huntsville, AL). Sequence information for additional microsatellites used for high resolution mapping of chromosome 16p was retrieved from either The Genome Data Base (GDB) (http://gdbwww.gdb.org/) or the CHLC (http://www.chlc.org/) database. Primers were designed such that amplification products for up to four markers could be co-electrophoresed without interference, to optimize the genotyping program. Primers were designed using the Oligot program (31) .
Twenty nanograms of genomic DNA were amplified by PCR in a final volume of 10 µl containing 100 nM each primer, 200 µM dNTPs, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl, 0.1% Triton X-100 and 0.025 U Taq DNA polymerase. Forward primers were labeled with [γ-32 P]ATP (3000 Ci/mmol; Dupont/ NEN) using T4 polynucleotide kinase (NEB). Reactions were processed on a MJR Thermal Cycler (PTC 100; MJ Research, Watertown, MA) using an initial denaturation at 96_C for 3 min, followed by 35 cycles of annealing for 1 min, extension at 72_C for 1 min and denaturation at 96_C for 15 s, with a final extension step at 72_C for 7 min. Optimized annealing temperatures ranged from 55 to 65_C. PCR products were multiplex-loaded in groups of up to four markers and size fractionated on 6% polyacrylamide sequencing gels containing 37.5% formamide, 8 M urea, 90 mM Tris-borate and 2 mM EDTA (Sequagelt; National Diagnostics). Gels were run at 60 W for 3.5-6 h, depending on the PCR product size, and exposed to Kodak XAR-5 film at -80_C for autoradiography. All markers were scored independently by two observers who were blind as to diagnosis and family structure.
Linkage analyses
Prior to embarking on the genome-wide screen we carried out extensive simulations using the computer program SLINK (32) , under the assumption of recessive inheritance and (near) complete penetrance. Results suggested an expected lod score of >4.0 for markers with a polymorphism information content (PIC) of ≥0.7, given the number of families and the average marker spacing we planned to use. For the genome-wide screen all 169 genotyped markers in 38 families were tested for linkage to affection status using a qualitative affected sib pair method as implemented in SIBPAL, in v.2.7 of SAGE (21) . SIBPAL provides an estimate of the proportion of alleles shared identical-by-descent in affected sib pairs.
After excess sharing on chromosome 16 was revealed, an additional 12 families were collected (a total of 50 families) and 12 chromosome 16 microsatellites were genotyped and used in subsequent linkage analyses. Of the 50 families available, 45 contained affected relative pairs other than parent-child and there were a total of 79 affected sib pairs. APM (23) and SIBPAL were used to investigate excess allele sharing on chromosome 16 among affected relative pairs (APM) or affected sib pairs (SIBPAL). The APM method makes use of identity-by-state sharing and a weighting function for marker allele matches that takes into account that it is more striking for affected relatives to share rare alleles. The weighting function f(p) = 1/√p, where p is the allele frequency, was used, as Weeks and Lange (23) have suggested that it is the best compromise between maintaining approximate normality with respect to the test statistic, T, and maximizing the power to detect linkage.
Two different disease models were utilized for the parametric analysis. For the autosomal recessive model we assumed a disease allele frequency of 2.5 × 10 -3 with 90% penetrance and a phenocopy rate of 10 -5 , while for the autosomal dominant model we assumed a disease allele frequency of 10 -5 with 50% penetrance and a phenocopy rate of 5 × 10 -6 . Two point linkage analysis was conducted using ILINK (24) with the FASTLINK program (33) for all 50 families under the two different models. Parametric and non-parametric multipoint linkage analysis was carried out using both GENEHUNTER (25) and VITESSE (27) . For the multipoint analyses intermarker distances and marker order were estimated using ILINK, based on genotype data from all available family members. Analyses for homogeneity were conducted using the HOMOG programs (26) , as detailed in Results, to test for general locus heterogeneity, for locus heterogeneity constrained to the region of interest and for allelic heterogeneity.
